Currencies / NRIX
NRIX: Nurix Therapeutics Inc
11.88
USD
0.16
(1.33%)
NRIX exchange rate has changed by -1.33% for today. During the day, the instrument was traded at a low of 11.78 and at a high of 12.33.
Follow Nurix Therapeutics Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
NRIX News
- Investing Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock
- Investing Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations
- Investing Nurix Therapeutics CFO van Houte sells $51,695 in shares
- Investing Morgan Stanley lowers Nurix stock price target to $16 on higher spend
- TipRanks Top 3 Trending Stocks, According to Analysts – 7/11/2025 - TipRanks.com
- Investing Stifel maintains Buy rating on Nurix stock, sees $4.5B peak sales potential
- Investing Nurix stock price target lowered to $26 by UBS on increased OpEx
- Investing Goldman Sachs initiates Nurix stock with Buy rating, $182 price target
- Investing Stifel reiterates Buy rating on Nurix stock, sees $4.5B peak sales potential
- Investing Nurix earnings beat by $0.19, revenue topped estimates
- Investing Nurix Therapeutics beats quarterly expectations on strong collaboration revenue
- Investing Nurix stock maintains Buy rating at H.C. Wainwright on positive BTK degrader data
- Seeking Alpha Tracking Baker Brothers Portfolio – Q1 2025 Update
- Investing Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Investing Nurix stock price target reiterated at $30 by UBS on positive trial data
- Investing Nurix stock price target raised to $28 from $27 at RBC Capital
- Investing Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni
- Investing Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr
- Investing Stifel analysts maintain Buy rating on Nurix stock after SNY deal
- Investing UnitedHealth, Biontech lead Monday’s market cap stock movers
- Investing Sanofi extends license option with Nurix’s STAT6 program
- Benzinga Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Nurix Therapeutics (NASDAQ:NRIX), Blueprint Medicines (NASDAQ:BPMC), Sanofi (NASDAQ:SNY)
- Investing Nurix secures additional $15 million from Sanofi license deal
- Investing Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Daily Range
11.78
12.33
Year Range
8.18
29.56
- Previous Close
- 11.89
- Open
- 12.04
- Bid
- 11.88
- Ask
- 12.18
- Low
- 11.78
- High
- 12.33
- Volume
- 2.183 K
- Daily Change
- -1.33%
- Month Change
- 4.30%
- 6 Months Change
- -38.79%
- Year Change
- -46.00%
31 July, Thursday
11:30
USD
- Act
- Fcst
- Prev
- 47.999 K
11:30
USD
- Act
- Fcst
- -68.3%
- Prev
- -1.6%
12:30
USD
- Act
- Fcst
- 0.4%
- Prev
- 0.2%
12:30
USD
- Act
- Fcst
- 2.6%
- Prev
- 2.7%
12:30
USD
- Act
- Fcst
- 0.2%
- Prev
- 0.1%
12:30
USD
- Act
- Fcst
- 2.3%
- Prev
- 2.3%
12:30
USD
- Act
- Fcst
- 0.2%
- Prev
- -0.1%
12:30
USD
- Act
- Fcst
- 0.7%
- Prev
- -0.4%
12:30
USD
- Act
- Fcst
- 0.0%
- Prev
- -0.3%
12:30
USD
- Act
- Fcst
- 0.9%
- Prev
- 0.9%
12:30
USD
- Act
- Fcst
- 1.0%
- Prev
- 1.2%
12:30
USD
- Act
- Fcst
- 0.7%
- Prev
- 0.8%
12:30
USD
- Act
- Fcst
- 224 K
- Prev
- 217 K
12:30
USD
- Act
- Fcst
- 1.966 M
- Prev
- 1.955 M
12:30
USD
- Act
- Fcst
- 222.299 K
- Prev
- 224.500 K
13:45
USD
- Act
- Fcst
- 42.4
- Prev
- 40.4
14:00
USD
- Act
- Fcst
- 2.3%
- Prev
- 2.0%
14:30
USD
- Act
- Fcst
- 2 B
- Prev
- 23 B
15:30
USD
- Act
- Fcst
- Prev
- 4.245%
15:30
USD
- Act
- Fcst
- Prev
- 4.265%